We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-2.24%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
+$368M
Cap. Flow
+$592M
Cap. Flow %
35.11%
Top 10 Hldgs %
42.19%
Holding
93
New
24
Increased
33
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$82.5M
2
APLT
Applied Therapeutics
APLT
+$64.9M
3
NUVL
Nuvalent
NUVL
+$56M
4
VERA icon
Vera Therapeutics
VERA
+$47.6M
5
CYTK icon
Cytokinetics
CYTK
+$44.1M

Top Sells

Rank Stock Value
1
NARI
Inari Medical, Inc. Common Stock
NARI
+$63.9M
2
INSM icon
Insmed
INSM
+$50.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$33.8M
4
JANX icon
Janux Therapeutics
JANX
+$22M
5
EW icon
Edwards Lifesciences
EW
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMED icon
26
Globus Medical
GMED
$10.9B
$26.9M 1.59%
+325,000
New +$25.6M
DNTH icon
27
Dianthus Therapeutics
DNTH
$6.03B
$23.4M 1.39%
1,075,000
+680,000
+172% +$17.5M
NYXH
28
Nyxoah
NYXH
$132M
$23.4M 1.39%
+2,924,216
New +$25.5M
VRNA
29
DELISTED
Verona Pharma
VRNA
$23M 1.36%
+495,000
New +$18.6M
IONS icon
30
Ionis Pharmaceuticals
IONS
$8.99B
$20.8M 1.23%
+595,000
New +$22.2M
LQDA icon
31
Liquidia Corp
LQDA
$7.93B
$20.7M 1.23%
1,760,000
+260,000
+17% +$2.84M
DAWN
32
DELISTED
Day One Biopharmaceuticals
DAWN
$18.2M 1.08%
1,440,000
-1,060,000
-42% -$14.7M
URGN icon
33
UroGen Pharma
URGN
$2.27B
$17.4M 1.03%
1,630,000
+1,230,000
+308% +$14.7M
LEGN icon
34
Legend Biotech
LEGN
$3.71B
$15.5M 0.92%
475,000
+350,000
+280% +$14.5M
ROIV icon
35
Roivant Sciences
ROIV
$25.4B
$14.8M 0.88%
+1,250,000
New +$14.8M
REGN icon
36
Regeneron Pharmaceuticals
REGN
$78.8B
$14.2M 0.84%
+20,000
New +$16.8M
ESTA icon
37
Establishment Labs
ESTA
$2.38B
$13.8M 0.82%
300,000
+260,000
+650% +$11.3M
TYRA icon
38
Tyra Biosciences
TYRA
$1.59B
$13.8M 0.82%
+990,000
New +$18M
BCAX
39
Bicara Therapeutics
BCAX
$1.79B
$12.4M 0.73%
710,000
+285,000
+67% +$5.93M
BDTX icon
40
Black Diamond Therapeutics
BDTX
$109M
$12M 0.71%
5,600,000
+571,500
+11% +$1.64M
SLDB icon
41
Solid Biosciences
SLDB
$863M
$11.4M 0.68%
2,850,000
+50,000
+2% +$275K
A icon
42
Agilent Technologies
A
$39.8B
$10.1M 0.6%
75,000
-25,000
-25% -$3.42M
APLT
43
DELISTED
Applied Therapeutics
APLT
$9.85M 0.58%
11,500,000
+10,355,000
+904% +$64.9M
PRGO icon
44
Perrigo
PRGO
$1.72B
$9.64M 0.57%
+375,000
New +$9.85M
NRIX icon
45
Nurix Therapeutics
NRIX
$2.57B
$9.14M 0.54%
485,000
+60,000
+14% +$1.38M
LXEO icon
46
Lexeo Therapeutics
LXEO
$363M
$7.9M 0.47%
1,200,000
+350,000
+41% +$2.76M
ZLAB icon
47
Zai Lab
ZLAB
$2.36B
$7.86M 0.47%
+300,000
New +$8.33M
CLDX icon
48
Celldex Therapeutics
CLDX
$3.24B
$7.71M 0.46%
+305,000
New +$8.29M
VYGR icon
49
Voyager Therapeutics
VYGR
$187M
$6.97M 0.41%
1,230,000
+740,000
+151% +$4.77M
ITOS
50
DELISTED
iTeos Therapeutics
ITOS
$6.91M 0.41%
900,000
-125,000
-12% -$1.07M
1
2
3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Vestal Point Capital held 93 positions worth $1.69B, up 28% from $1.32B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Vestal Point Capital deployed $592M of net new capital in Q4 2024, opening 24 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 800,000 shares worth $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $50.4M trimmed.

  • Vestal Point Capital's largest Q4 2024 buy was Merck: 800,000 shares worth $79.6M.
  • Vestal Point Capital added most to Applied Therapeutics in Q4 2024, an estimated $64.9M increase.
  • Vestal Point Capital's biggest Q4 2024 reduction was Insmed, cutting an estimated $50.4M.
  • Vestal Point Capital fully exited Inari Medical, Inc. Common Stock in Q4 2024, selling an estimated $63.9M.
  • Vestal Point Capital's ten largest holdings make up 42% of its $1.69B portfolio in Q4 2024.
  • Vestal Point Capital opened 24 new positions and closed 20 in Q4 2024.
  • Vestal Point Capital's portfolio value rose 28% quarter-over-quarter to $1.69B.

Based on Vestal Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.